The HCPLive Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for C difficile, IBS and IBD, Crohn's disease, and more.
May 7th 2024
Geneoscopy's ColoSense received FDA approval on May 06, 2024 based on data from the phase 3 CRC-PREVENT trial.
Biden Administration, CMS Reveal First 10 Drugs Set for Price Negotiation
August 29th 2023On August 29, 2023, the Biden Administration debuted the list of the first 10 drugs identified for price negotiation under the Inflation Reduction Act. The list, which includes agents indicated for diabetes, heart failure, GI conditions, and arthritis, accounted for more than $50 billion in spending during the evaluation period.
AbbVie Submits Application to FDA for Risankizumab in Ulcerative Colitis
August 28th 2023AbbVie submitted regulatory applications to the FDA and EMA for rizankizumab 1200 mg intravenous induction dose and 180 mg and 360 mg subcutaneous maintenance dose following successful Phase 3 trials INSPIRE and COMMAND.
Age, Prior Vaccination Predict Future Vaccine Receipt in Patients with IBD
August 24th 2023When evaluating patient-education strategies among individuals with IBD, investigators found vaccine uptake was unaffected by educational videos and text-based interventions, identifying prior vaccine receipt as the strongest predictor of future vaccination.
No Difference in Pediatric Growth Rates with Infliximab Biosimilar vs Reference Agent
July 21st 2023A single-center retrospective study is offering clinicians insight into the effects of biosimilar infliximab use on weight, height, and BMI trajectories in pediatric patients with inflammatory bowel disease.
Study Identifies Potential Link Between Gut Microbiome and Atherosclerosis
July 12th 2023Using data from more than 8500 patients from a bioimaging study, investigators took a deep dive into potential associations between gut microbiome and subclinical atherosclerosis in adults without a history of cardiovascular disease
Investigators Find Demographic Predictors of Up-to-Date Colorectal Cancer Screenings
There were several individual predictors including sex, age, recent visits with a primary care provider, distance to nearest endoscopy facility, and insurance type, as well as county-level predictors, such as percentage of residents with a high school education, without insurance, and unemployed as being up-to-date.
Autocancellation of Uncollected CDI Test Orders Does Not Reduce Infection Rate
The reported C difficile healthcare-acquired infections rates per 10,000 patient days did not significantly change. The rates were 8.07 in the 6-month preintervention period and 8.77 in the intervention period for facilities A and B combined.
Mirikizumab Bests Placebo in Treating Patients With Ulcerative Colitis
There were higher percentages of patients treated with mirikizumab that had clinical remission at week 12 of the induction trial compared to the placebo group. This was also true at week 40 of the maintenance trial.